New Player on an old field; the Keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome

Current Diabetes Reviews

Volumn 9, Issue 2, 2013, Pages 137-145

  Chartoumpekis, Dionysios V ^a   Kensler, Thomas W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Keap1; Metabolism; Nrf2; Obesity; Oxidative stress

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RETINOID X RECEPTOR ALPHA; SCAVENGER RECEPTOR BI; TRANSCRIPTION FACTOR NRF2;

ADIPOSE TISSUE; BONE MARROW TRANSPLANTATION; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; ENERGY EXPENDITURE; ENERGY METABOLISM; GENOTYPE; GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR TRANSPORT; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER REGENERATION; LUNG GAS EXCHANGE; METABOLIC REGULATION; METABOLIC STRESS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TISSUE SECTION; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

EID: 84877809314     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811309020005     Document Type: Review

References (90)

1. Rejeski, W.J., E.H. Ip, A.G. Bertoni, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med, 2012; 366(13): p. 1209-17.
2. Goodpaster, B.H., J.P. Delany, A.D. et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA, 2010; 304(16): p. 1795-802.
3. Flegal, K.M., M.D. Carroll, C.L. Ogden, and L.R. Curtin, Prevalence and trends in obesity among US adults, 1999-2008. JAMA, 2010; 303(3): p. 235-41.
4. CDC (2011) National Diabetes Fact Sheet, 2011.
5. Miranda, P.J., R.A. DeFronzo, R.M. Califf, and J.R. Guyton, Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J, 2005; 149(1): p. 33-45.
6. Ford, E.S., W.H. Giles, and W.H. Dietz, Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 2002; 287(3): p. 356-9.
7. O'Neil, P.M., S.R. Smith, N.J. Weissman, M.C. et al. Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. Obesity (Silver Spring), 2012; 20(7): p. 1426-36.
8. Gadde, K.M., D.B. Allison, D.H. Ryan, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet, 2011; 377(9774): p. 1341-52.
9. DeFronzo, R.A. and A.M. Goodman, Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med, 1995; 333(9): p. 541-9.
10. Perfetti, R. and A. Ahmad, Novel sulfonylurea and nonsulfonylurea drugs to promote the secretion of insulin. Trends Endocrinol Metab, 2000; 11(6): p. 218-23.
11. Yki-Jarvinen, H., Thiazolidinediones. N Engl J Med, 2004; 351(11): p. 1106-18.
12. Komajda, M., J.J. McMurray, H. Beck-Nielsen, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J, 2010; 31(7): p. 824-31.
13. Cariou, B., B. Charbonnel, and B. Staels, Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab, 2012; 23(5): p. 205-15.
14. Holst, J.J., Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs, 2004; 9(1): p. 155-66.
15. Van de Laar, F.A., P.L. Lucassen, R.P. Akkermans, E.H. Van de Lisdonk, G.E. Rutten, and C. Van Weel, Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2005(2); p. CD003639.
16. Grundy, S.M., J.I. Cleeman, C.N. Merz, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004; 110(2): p. 227-39.
17. Liao, J.K. and U. Laufs, Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol, 2005; 45: p. 89-118.
18. Urakawa, H., A. Katsuki, Y. Sumida, et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab, 2003; 88(10): p. 4673-6.
19. Furukawa, S., T. Fujita, M. Shimabukuro, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest, 2004; 114(12): p. 1752-61.
20. Evans, J.L., B.A. Maddux, and I.D. Goldfine, The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal, 2005; 7(7-8): p. 1040-52.
21. Houstis, N., E.D. Rosen, and E.S. Lander, Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 2006; 440(7086): p. 944-8.
22. Kensler, T.W., N. Wakabayashi, and S. Biswal, Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol, 2007; 47: p. 89-116.
23. Sykiotis, G.P. and D. Bohmann, Stress-activated cap'n'collar transcription factors in aging and human disease. Sci Signal, 2010; 3(112): p. re3.
24. Kobayashi, M. and M. Yamamoto, Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul, 2006; 46: p. 113-40.
25. Motohashi, H. and M. Yamamoto, Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med, 2004; 10(11): p. 549-57.
26. Wakabayashi, N., A.T. Dinkova-Kostova, W.D. Holtzclaw, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci U S A, 2004; 101(7): p. 2040-5.
27. Kwak, M.K., N. Wakabayashi, K. Itoh, H. Motohashi, M. Yamamoto, and T.W. Kensler, Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem, 2003; 278(10): p. 8135-45.
28. Lee, J.M., J. Li, D.A. Johnson, et al. Nrf2, a multi-organ protector? FASEB J, 2005; 19(9): p. 1061-6.
29. Itoh, K., T. Chiba, S. Takahashi, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun, 1997; 236(2): p. 313-22.
30. Chan, K., R. Lu, J.C. Chang, and Y.W. Kan, NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci U S A, 1996; 93(24): p. 13943-8.
31. Khor, T.O., M.T. Huang, A. Prawan, et al. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila), 2008; 1(3): p. 187-91.
32. Ramos-Gomez, M., M.K. Kwak, P.M. Dolan, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A, 2001; 98(6): p. 3410-5.
33. Rangasamy, T., J. Guo, W.A. Mitzner, et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med, 2005; 202(1): p. 47-59.
34. Calkins, M.J., D.A. Johnson, J.A. Townsend, et al. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal, 2009; 11(3): p. 497-508.
35. Enomoto, A., K. Itoh, E. Nagayoshi, et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci, 2001; 59(1): p. 169-77.
36. Wakabayashi, N., S.L. Slocum, J.J. Skoko, S. Shin, and T.W. Kensler, When NRF2 talks, who's listening? Antioxid Redox Signal, 2010; 13(11): p. 1649-63.
37. Surwit, R.S., C.M. Kuhn, C. Cochrane, J.A. McCubbin, and M.N. Feinglos, Diet-induced type II diabetes in C57BL/6J mice. Diabetes, 1988; 37(9): p. 1163-7.
38. Tanaka, Y., L.M. Aleksunes, R.L. Yeager, et al. NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther, 2008; 325(2): p. 655-64.
39. Pi, J., L. Leung, P. Xue, et al. Deficiency in the nuclear factor E2-related factor-2 transcription factor results in impaired adipogenesis and protects against diet-induced obesity. J Biol Chem, 2010; 285(12): p. 9292-300.
40. Chawla, A., E.J. Schwarz, D.D. Dimaculangan, and M.A. Lazar, Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 1994; 135(2): p. 798-800.
41. Kubota, N., Y. Terauchi, H. Miki, H. Tamemoto, T. Yamauchi, K. Komeda, S. Satoh, R. Nakano, C. et al., PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell, 1999; 4(4): p. 597-609.
42. Chartoumpekis, D.V., P.G. Ziros, A.I. Psyrogiannis, et al. Habeos, Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes, 2011; 60(10): p. 2465-73.
43. Kharitonenkov, A., T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath, G.E. Sandusky, L.J. Hammond, J.S. Moyers, R.A. Owens, J. Gromada, J.T. Brozinick, E.D. Hawkins, V.J. Wroblewski, D.S. Li, F. Mehrbod, S.R. Jaskunas, and A.B. Shanafelt, FGF-21 as a novel metabolic regulator. J Clin Invest, 2005; 115(6): p. 1627-35.
44. Coskun, T., H.A. Bina, M.A. Schneider, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 2008; 149(12): p. 6018-27.
45. Itoh, N. and D.M. Ornitz, Functional evolutionary history of the mouse Fgf gene family. Dev Dyn, 2008; 237(1): p. 18-27.
46. Adams, A.C. and A. Kharitonenkov, FGF21: The Center of a Transcriptional Nexus in Metabolic Regulation. Curr Diabetes Rev, 2012; 8(4): p. 285-93.
47. Lin, J., C. Handschin, and B.M. Spiegelman, Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab, 2005; 1(6): p. 361-70.
48. Meher, A.K., P.R. Sharma, V.A. Lira, M. Yamamoto, T.W. Kensler, Z. Yan, and N. Leitinger, Nrf2 deficiency in myeloid cells is not sufficient to protect mice from high-fat diet-induced adipose tissue inflammation and insulin resistance. Free Radic Biol Med, 2012; 52(9): p. 1708-15.
49. Sauer, B. and N. Henderson, Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A, 1988; 85(14): p. 5166-70.
50. Yates, M.S., M. Tauchi, F. Katsuoka, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther, 2007; 6(1): p. 154-62.
51. Shin, S., J. Wakabayashi, M.S. Yates, et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol, 2009; 620(1-3): p. 138-44.
52. Riant, E., A. Waget, H. Cogo, J.F. Arnal, R. Burcelin, and P. Gourdy, Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology, 2009; 150(5): p. 2109-17.
53. Yu, Z., W. Shao, Y. Chiang, et al. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia, 2011; 54(4): p. 922-34.
54. Okawa, H., H. Motohashi, A. Kobayashi, H. Aburatani, T.W. Kensler, and M. Yamamoto, Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun, 2006; 339(1): p. 79-88.
55. Xu, J., S.R. Kulkarni, A.C. Donepudi, V.R. More, and A.L. Slitt, Enhanced Nrf2 Activity Worsens Insulin Resistance, Impairs Lipid Accumulation in Adipose Tissue, and Increases Hepatic Steatosis in Leptin-Deficient Mice. Diabetes, 2012.
56. Hou, Y., P. Xue, Y. Bai, et al. Nuclear factor erythroid-derived factor 2-related factor 2 regulates transcription of CCAAT/enhancer-binding protein beta during adipogenesis. Free Radic Biol Med, 2012; 52(2): p. 462-72.
57. Yeh, W.C., Z. Cao, M. Classon, and S.L. McKnight, Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev, 1995; 9(2): p. 168-81.
58. Shin, S., N. Wakabayashi, V. Misra, et al. NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis. Mol Cell Biol, 2007; 27(20): p. 7188-97.
59. Alexander, D.L., L.G. Ganem, P. Fernandez-Salguero, F. Gonzalez, and C.R. Jefcoate, Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. J Cell Sci, 1998; 111 (Pt 22): p. 3311-22.
60. Chorley, B.N., M.R. Campbell, X. Wang, et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res, 2012.
61. D'Autreaux, B. and M.B. Toledano, ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol, 2007; 8(10): p. 813-24.
62. Lee, H., Y.J. Lee, H. Choi, E.H. Ko, and J.W. Kim, Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion. J Biol Chem, 2009; 284(16): p. 10601-9.
63. Chartoumpekis, D.V., P.G. Ziros, G.P. Sykiotis, et al. Nrf2 activation diminishes during adipocyte differentiation of ST2 cells. Int J Mol Med, 2011; 28(5): p. 823-8.
64. Nielsen, R., T.A. Pedersen, D. Hagenbeek, et al. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev, 2008; 22(21): p. 2953-67.
65. Wakabayashi, N., S. Shin, S.L. Slocum, et al. Regulation of notch1 signaling by nrf2: implications for tissue regeneration. Sci Signal, 2010; 3(130): p. ra52.
66. Garces, C., M.J. Ruiz-Hidalgo, J. Font de Mora, et al. Notch-1 controls the expression of fatty acid-activated transcription factors and is required for adipogenesis. J Biol Chem, 1997; 272(47): p. 29729-34.
67. Nichols, A.M., Y. Pan, A. Herreman, et al. Notch pathway is dispensable for adipocyte specification. Genesis, 2004; 40(1): p. 40-4.
68. McCullough, A.J., Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol, 2006; 40 Suppl 1: p. S17-29.
69. Huang, J., I. Tabbi-Anneni, V. Gunda, and L. Wang, Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism. Am J Physiol Gastrointest Liver Physiol, 2010; 299(6): p. G1211-21.
70. Rinella, M.E. and R.M. Green, The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol, 2004; 40(1): p. 47-51.
71. Yao, Z.M. and D.E. Vance, Reduction in VLDL, but not HDL, in plasma of rats deficient in choline. Biochem Cell Biol, 1990; 68(2): p. 552-8.
72. Rinella, M.E., M.S. Elias, R.R. Smolak, T. Fu, J. Borensztajn, and R.M. Green, Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res, 2008; 49(5): p. 1068-76.
73. Chowdhry, S., M.H. Nazmy, P.J. Meakin, et al. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med, 2010; 48(2): p. 357-71.
74. Sugimoto, H., K. Okada, J. Shoda, et al. Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol, 2010; 298(2): p. G283-94.
75. Zhang, Y.K., R.L. Yeager, Y. Tanaka, and C.D. Klaassen, Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. Toxicol Appl Pharmacol, 2010; 245(3): p. 326-34.
76. Yates, M.S., Q.T. Tran, P.M. Dolan, et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoidtreated mice. Carcinogenesis, 2009; 30(6): p. 1024-31.
77. Kitteringham, N.R., A. Abdullah, J. Walsh, et al. Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. J Proteomics, 2010; 73(8): p. 1612-31.
78. Wallace, T.M. and D.R. Matthews, The assessment of insulin resistance in man. Diabet Med, 2002; 19(7): p. 527-34.
79. Kim, J.K., A. Zisman, J.J. Fillmore, et al., Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest, 2001; 108(1): p. 153-60.
80. Lazar, M.A. and M.J. Birnbaum, Physiology. De-meaning of metabolism. Science, 2012; 336(6089): p. 1651-2.
81. Mitsuishi, Y., K. Taguchi, Y. Kawatani, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell, 2012; 22(1): p. 66-79.
82. Salazar, M., A.I. Rojo, D. Velasco, R.M. de Sagarra, and A. Cuadrado, Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem, 2006; 281(21): p. 14841-51.
83. Rada, P., A.I. Rojo, S. Chowdhry, M. McMahon, J.D. Hayes, and A. Cuadrado, SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol, 2011; 31(6): p. 1121-33.
84. Yu, Z.W., D. Li, W.H. Ling, and T.R. Jin, Role of nuclear factor (erythroid-derived 2)-like 2 in metabolic homeostasis and insulin action: A novel opportunity for diabetes treatment? World J Diabetes, 2012; 3(1): p. 19-28.
85. Vomhof-Dekrey, E.E. and M.J. Picklo, Sr., The Nrf2-antioxidant response element pathway: a target for regulating energy metabolism. J Nutr Biochem, 2012.
86. Sykiotis, G.P., I.G. Habeos, A.V. Samuelson, and D. Bohmann, The role of the antioxidant and longevity-promoting Nrf2 pathway in metabolic regulation. Curr Opin Clin Nutr Metab Care, 2011; 14(1): p. 41-8.
87. Hong, D.S., R. Kurzrock, J.G. Supko, et al., A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res, 2012; 18(12): p. 3396-3406.
88. Egner, P.A., J.G. Chen, J.B. Wang, et al. Bioavailability of Sulforaphane from two broccoli sprout beverages: results of a shortterm, cross-over clinical trial in Qidong, China. Cancer Prev Res (Phila), 2011; 4(3): p. 384-95.
89. Ren, D., N.F. Villeneuve, T. Jiang, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A, 2011; 108(4): p. 1433-8.
90. Magesh, S., Y. Chen, and L. Hu, Small Molecule Modulators of Keap1-Nrf2-ARE Pathway as Potential Preventive and Therapeutic Agents. Med Res Rev, 2012; 32(4): p. 687-726.